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are obstructive sleep apnea (4%),[2,3] chronic insomnia (5%),[4] 
and periodic limb movement disorder (3.9%).[5] Sleep disorders 
are known to be associated with diseases and problems such 
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ABSTRACT
Introduction: Community pharmacists are in a suitable position to give advice and provide appropriate services 
related to sleep disorders to individuals who are unable to easily access sleep clinics. An intervention with 
proper objective measure can be used by the pharmacist to assist in consultation. Objectives: The study 
objectives are to evaluate: (1) The effectiveness of a community pharmacybased intervention in managing 
sleep disorders and (2) the role of actigraph as an objective measure to monitor and followup individuals with 
sleeping disorders. Methods and Instruments: The intervention care group (ICG) completed questionnaires to 
assess sleep scale scores (Epworth Sleepiness Scale [ESS] and Insomnia Severity Index [ISI]), wore a wrist 
actigraph, and completed a sleep diary. Sleep parameters (sleep efficiency in percentage [SE%], total sleep 
time, sleep onset latency, and number of nocturnal awakenings) from actigraphy sleep report were used for 
consultation and to validate sleep diary. The usual care group (UCG) completed similar questionnaires but 
received standard care. Results: Pre and postmean scores for sleep scales and sleep parameters were 
compared between and within groups. A significant difference was observed when comparing pre and 
postmean scores for ISI in the ICG, but not for ESS. For SE%, an increase was found in the number of 
subjects rated as “good sleepers” at postassessment in the ICG. Conclusions: ISI scores offer insights into 
the development of a community pharmacybased intervention for sleeping disorders, particularly in those 
with symptoms of insomnia. It also demonstrates that actigraph could provide objective sleep/wake data to 
assist community pharmacists during the consultation.
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W orldwide, prevalence rates of sleep disorders are high and increasingly encountered in primary healthcare settings. 
In Australia, the prevalence rate of sleep disorders in the general 
population are considered to be high, and are estimated to affect 
about 1.5 million or 8.9% of the population;[1] the most common 
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as diabetes, hypertension, cardiovascular diseases, impaired 
cognitive function, poor school or work performance, and 
memory disturbance.[68]
New interventions are needed to provide more accessible primary 
care options to assist those with/or at risk of sleep disorders, as 
alternatives to sleep specialists who often have longer waiting 
times, and can be expensive if additional procedures are required. 
In fact, it was found that treatment under a primary healthcare 
model, compared with a specialist model, resulted in similar 
patient outcomes.[9] Community pharmacists can offer primary 
assistance to help individuals with sleeping disorders because 
they are usually more accessible, and also highly trained in 
therapeutics, medicines, diseases state management, health 
education, and facetoface counseling.[10] This, therefore, places 
them in an ideal position to play a role in the management of 
sleeprelated disorders, by initiating conversation, discussing 
medicines, and providing continuous assessments. Monitoring 
and following up individuals with sleeping disorders can be 
difficult without appropriate instruments or standard intervening 
measures. While most previous research on community 
pharmacybased interventions for sleep disorders focused 
on developing screening tools,[1114] there is an opportunity 
to develop an intervention that monitors and followsup the 
patients, particularly after treatment was sought.
Using a stepwise approached, this feasibility study was 
conducted to tackle “poor sleep” in walkin individuals who 
attended the community pharmacy seeking help for the 
condition. An intervening model of care inclusive of baseline 
assessment, monitoring, and followup to gain feedback on 
sleep, was developed. For this purpose, a wristwatch device, 
actigraph, was utilized. Being convenient and portable, 
actigraph is a practical device for use in the community and 
homebased environment.[1517] While assessing sleep/wake 
patterns is difficult when selfreporting is poor or subjective 
measuring tools are used, actigraph can overcome this challenge 
by providing objective and graphical data, and by measuring 
gross motor activities to infer sleep/wake patterns.[18] Actigraph 
can identify certain sleep parameters and can also be used 
to validate selfreported feedback whenever selfreport and 
actigraphy data are used concurrently.[19]
This paper describes an intervention developed to assist the 
pharmacist in improving the management of sleep disorders at 
the community pharmacy. The study objectives are to evaluate 
the effectiveness of a community pharmacybased intervention 
in managing sleep disorders and to evaluate the role of actigraph 
as an objective measure to monitor and followup individuals 
who attended community pharmacy seeking assistance for 
sleeping disorders.
Ethical approval
This project was approved by the School of Pharmacy Ethics 
Committee, University of Queensland. This study also has 
been registered with the Australia New Zealand Clinical Trial 
Registry (ANZCTR1261200082585) for conducting research 
using human subjects.
Methods and Instruments
A complete study protocol has been published in BMC Health 
Services Research.[20]
Study design and setting
This study was a communitybased intervention, prospective 
controlled trial, with one intervention group and one control 
group, and involved three community pharmacies in Brisbane 
area with similar demographic criteria and physical locations.
Study population
Participants
Participants were recruited among community pharmacy 
customers who attended the participating pharmacies seeking 
assistance for sleeping disorders and “poor sleep.” Eligible 
participants were walkin customers, aged 18 years and above, 
could read, wrote, and spoke adequate English to complete 
the questionnaire and consultation sessions, not pregnant, 
not currently under treatment with continuous positive airway 
pressure and agreed to give consent.[20]
Community pharmacies
Community pharmacies were contacted from publically available 
lists. Pharmacies which met the study criteria[20] were contacted 
through telephone and informed about the project, and were invited 
to participate. If the pharmacist expressed an interest, a research 
officer arranged a facetoface meeting to further discuss the study 
and obtained consent. Pharmacies were later assigned to either the 
intervention care group (ICG) or usual care group (UCG). Upon 
consent, the ICG pharmacists and pharmacy staff received a brief 
session (about 20–30 min) in the pharmacy about the actigraph, 
the sleep diary, the questionnaires, and the forms related to the 
study, and were provided the actigraph user’s manual. A researcher 
also assisted with the installation of proprietary software to a 
computer in the pharmacy, which enabled data to be downloaded 
from the actigraph to generate graphical sleep/wake data, as in 
Figures 1 and 2[22] for each participant. The ICG pharmacy also had 
a private counseling area within the premise and agreed to followup 
the participants for 2 weeks from baseline.
The UCG pharmacy provided the participants with standard 
care for sleep disorders, based on the usual practice in the 
community pharmacy in Australia.[21] The UCG pharmacy 
also followedup the participants after 2 weeks from baseline.
Baseline, monitoring, and followup
The complete duration of the study was 2 weeks [Figure 3]. 
The participants were conveniently assigned to the ICG or 
UCG, depending on which recruited pharmacy they attended. 
Recruitment was conducted from February 1, 2013, until May 
15, 2013, with the last 2week followup session completed on 
May 30, 2013.
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All participants in both groups completed a set of baseline 
questionnaires. Each participant in the ICG received an 
“intervention package” consisting of: (1) A wrist actigraph, 
(2) a sleep diary and (3) educational information about sleep 
disorders, sleep health management, sleep hygiene, and healthy 
lifestyle to improve sleep, via access to a website, developed 
purposely for this study.[20]
In the ICG, followup sessions were conducted at twotime 
points to download the actigraphy data and generate an 
individual sleep report. This was used to validate participants’ 
selfreported sleep diary and assess the sleep/wake patterns, 
and to counsel them regarding sleep. Upon completion of the 
study, participants returned the actigraph and completed a set 
of study completion questionnaires. For the ICG, the protocol 
included referral to a general practitioner (if required), after 
2 weeks of followup. Meanwhile, the UCG received standard 
care for sleep disorders with a followup at week 2, via email or 
mail, to complete a similar set of study completion questionnaire 
as the ICG.[20]
Assessment instruments
Actigraph
The ICG received the SBV2 Readiband™ (Fatigue Science, 
Honolulu) wristworn actigraph to record sleep/wake patterns. 
The device was worn 24 h/day for 7 days before the participants 
revisited the pharmacy for their first followup, and then for 
a further 7 days after the first followup before returning to 
the pharmacy for final assessment to complete the study. To 
determine the acceptability and feasibility of this device for use 
in homebased settings, a feasibility study was conducted.[22]
The hardware consists of an accelerometer with the sensitivity 
to continuously track wristmovement and keep these data 
for further analyses. The actigraph was initialized to collect 
data in 1 min epochs. The collected data were then wirelessly 
downloaded to a computer for analyses using Nordic 2.4 
GHz ANT transceiver. Data were analyzed using proprietary 
software (Fatigue Science, Honolulu) and individualized reports 
were automatically generated for each participant.
Figure 1: Example of a graphical sleep/wake data plot from a normal sleeper downloaded from the actigraph using the proprietary software. 
Sleep onset time, wake after sleep onset, and duration of sleep (total sleep time per day) can be obtained from this plot
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Sleep diary
Each ICG participant also received a sleep diary to selfrecord 
14 days of sleep onset latency (SOL), number of nocturnal 
awakenings (NWAK) and total sleep time (TST), plus 
information related to sleep hygiene, sleeprelated lifestyle, and 
other factors that might interrupted sleep.
Baseline questionnaires
All participants were required to complete a set of 
selfadministered questionnaires, which included:
•  Demographic and sleep related lifestyle informat ion 
(sleep environment, smoking, alcohol consumption, 
and caffeinated drinks intake), modified from the 
validated Pharmacy Tool for Assessment of Sleep 
Health (POTASH)[13,23]
•   Sleep health assessment (adapted from the POTASH) – to 
assess sleep scale scores, utilizing the Epworth Sleepiness 
Scale (ESS)[24,25] and the Insomnia Severity Index (ISI).[26,27]
Study completion questionnaires
At week 2, to complete the study, the participants were required 
to complete a set of selfadministered study completion 
questionnaires, which included similar assessment of sleep 
scale (ESS and ISI) scores in place.
Figure 2: Example of sleep statistics downloaded from actigraphy data for a normal sleeper (Average amount of sleep per 24 hour period (hours/
day) = average of total sleep time (TST) per 24 hour period (hours/day). Median time to fall asleep = median of sleep onset latency (SOL), 
minutes. Average number of times you woke up at night = number of nocturnal awakenings (NWAK), times. Percentage of time in bed actually 
spent sleeping = Sleep efſ ciency percentage (SE%). Average start time of the longest sleep period = average of sleep onset time)
Intervention Pharmacy
(Recruited Intervention
Care Group, ICG)
Control Pharmacy
(Recruited Standard Care
Group, UCG)
‘Walk-in’ customers with sleeping
 disorders (total number of invited
 customers was not recorded by the 
pharmacists)
‘Walk-in’ customers with sleeping
 disorders (total number of invited 
customers was not recorded by the 
pharmacists)
Agreed & assessed for eligibility
(n = 30)
Agreed & assessed for eligibility
(n = 23)
Not eligible
(n = 5)
YES YES
Participate
(n = 25)
Participate (n = 21)
Withdraw from study (n = 2)
1 week
1 week
Follow-up 1 (n = 20)
Withdraw from study (n = 5)
2 weeks
Follow-up 2 / End of study
N = 20
Follow-up / End of study
N = 21
Figure 3: Flowchart of participants’ recruitment and follow up
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Statistical analysis
Sleep parameters measurement, that is, sleep efficiency in 
percentage (SE%), TST, SOL, and NWAK for each participant 
obtained from the sleep diary and actigraphy sleep report, 
were averaged from all the data recorded during the 2week 
period (recorded as “pre” (week 1) and “post” (week 2) mean 
scores). In this analysis, there was no discrimination between 
weekdays and weekend data. Sleep scale scores recorded at 
baseline and week 2 were averaged to mean scores for analysis. 
Data were analyzed using SPSS 20.0 for windows (IBM). 
Considering alpha level of 0.05 for all statistical tests, and using 
descriptive, paired ttest and independent ttest, demographic 
characteristics, sleep scale scores, and pairwise differences of 
sleep parameters mean scores between and within groups were 
compared.
Results
Demographic and sleeprelated characteristics
A total of fortyone (n = 41) customers participated and 
completed all parts of the study for analyses (ICG, n = 20; 
UCG, n = 21). The proportion of females was 68.3%. The 
predominant age group was between 46 and 60 years of 
age (36.6%) and followed by 31–45 years (24.4%). Almost 
half of the participants (48.8%) were college/university 
educated, and 29.3% were professional workers. In terms 
of ethnicity, most identified as Caucasian (53.7%), and 
followed by European (26.8%). Most participants (70.7%) 
were not working on shift, and 61% slept with a bed partner. 
The majority of participants (92.7%) were having difficulties 
sleeping (which puts them at higher risk of significant 
insomnia), but very few reported experiencing daytime 
sleepiness (17%). Table 1 shows the details of the participants’ 
sleeprelated characteristics.
Effectiveness of the intervention
Assessments were based on these indicators:
•   Changes in mean scores for ESS and ISI, between and within 
groups, at baseline and week 2
•  Changes in mean scores for SE%, TST, NWAK, and SOL, 
between pre and postactigraphy sleep report data in the 
ICG.
When comparing sleep scale mean scores between 
groups [Table 2], the ICG showed a lower postESS mean score 
compared to the UCG, although it was insignificant. However, 
a significant difference was found when comparing postISI 
mean scores between the ICG and the UCG. A marginal 
significant difference (P = 0.074) was found when comparing 
pre and postESS mean scores in the ICG [Table 3]. Meanwhile, 
comparisons of mean scores between pre and postISI within 
the ICG observed significant differences.
Comparisons of these mean scores (SE%, TST, SOL, and 
NWAK), assessed at twotime points in the ICG; showed no 
significant differences at all times. However, to better understand 
changes in SE%, it was categorized into 4levels[18] [Table 4],  and 
a slight increase was found in the number of subjects who rated 
themselves as “good sleepers” at postassessment.
Table 1: Baseline sleep related characteristics of the 
participants
Characteristics n (%) 
(n= 41)
ICG (n= 20)
n (%)
UCG (n= 21)
n (%)
Shift work
Yes 9 (22.0) 4 (9.8) 5 (12.2)
No 29 (70.7) 15 (36.6) 14 (34.1)
Not specified 3 (7.3) 1 (2.4) 2 (4.9)
Caffeinated drink intake (cup)/day
Do not drink 11 (26.8) 5 (12.2) 6 (14.6)
1 5 (12.2) 2 (4.9) 3 (7.3)
2-3 21 (51.2) 11 (26.8) 10 (24.4)
4-5 4 (9.8) 2 (4.9) 2 (4.9)
Alcoholic drink consumption
Do not drink 16 (39.0) 10 (24.4) 6 (14.6)
1-2 times/month 10 (24.4) 5 (12.2) 5 (12.2)
1-2 times/week 6 (14.6) 3 (7.3) 3 (7.3)
2-3 times/week 4 (9.8) - 4 (9.8)
≥ 4 times/week 5 (12.2) 2 (4.9) 3 (7.3)
Smoking status
Smoker 3 (7.3) 2 (4.9) 1 (2.4)
Nonsmoker 38 (92.7) 18 (43.9) 20 (48.8)
ESS
< 10 34 (82.9) 15 (36.6) 19 (46.3)
≥ 10 6 (14.6) 5 (12.2) 1 (2.4)
≥ 18 1 (2.4) - 1 (2.4)
ISI
0-7 3 (7.3) 1 (2.4) 2 (4.9)
8-14 15 (36.6) 9 (22.0) 6 (14.6)
15-21 16 (39.0) 6 (14.6) 10 (24.4)
22-28 7 (17.1) 4 (9.8) 3 (7.3)
Explanation of sleep scale scores: ESS (range 0-24): Cut-off point ≥ 10, 
< 10 (reduce daytime sleepiness), ≥ 10 (sleepy), ≥ 18 (very sleepy), 
ISI (range 0-28): Cut-off point≥ 10, 0-7: No clinically significant insomnia, 
8-14: Sub-threshold insomnia, 15-21: Clinical insomnia (moderate severity), 
22-28: Clinical insomnia (severe). A cut-off score of 10 was optimal for 
detecting insomnia cases in the community sample. ESS: Epworth Sleepiness 
Scale, ISI : Insomnia Severity Index, ICG: Intervention care group, UCG: 
Usual care group
Table 2: Comparisons between groups for sleep scale scores
Instrument Group/
pre/post
Mean (SD) 
scores
Mean 
differences
95% CI of the 
difference
Significant 
(two tailed), P
ESS Pre
ICG 5.20 (5.47) 1.01 − 2.10-4.12 0.515
UCG 4.19 (4.33)
Post
ICG 4.05 (4.14) − 0.38 − 2.30-2.24 0.772
UCG 4.43 (4.15)
ISI Pre
ICG 15.45 (6.68) − 0.50 − 4.27-3.27 0.789
UCG 15.95 (5.19)
Post
ICG 11.10 (5.80) − 4.14 − 7.60-− 0.68 0.020*
UCG 15.24 (5.15)
* P< 0.05. ICG n= 20, UCG n= 21. Pre - baseline, Post - week 2. 
SD: Standard deviation, ICG: Intervention care group, UCG: Usual 
care group, CI : Confidence interval, ESS: Epworth Sleepiness Scale, 
ISI : Insomnia Severity Index
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Role of actigraph
To evaluate the use of actigraph as an objective sleep assessment 
instrument, sleep parameter mean scores obtained from the 
actigraphy sleep report and the sleep diary were compared 
between groups at twotime points. The agreement was found 
between these two methods [Table 5].
Discussion
This study was developed to compare the standard care practice 
for managing sleep disorders in the community pharmacy with 
an intervention that utilized actigraph as an objective sleep 
assessment instrument to monitor and followup individuals 
with sleeping disorders after treatment was sought.
The insignificant findings for the ESS mean scores may be 
owing to the small number of participants who were at higher 
risk of excessive daytime sleepiness. However, in contrast, the 
differences between and within groups for ISI mean scores were 
observed at week 2. These results were consistent with other 
studies that used actigraph to assess insomnia patients.[17,32,33] 
Although the study initial aim was generally to focus on “poor 
sleep,” the majority of participants were found to be at higher 
risk of insomnia at baseline. Hence, the intervention appeared to 
be most effective in those with this condition. Another possible 
explanation is that in this study population, it could be easier 
to detect a difference due to a larger number of participants 
who were identified to be at risk of insomnia.
The intervention also included two consultation sessions, 
consisted of elements such as sleep education, sleep hygiene 
and discussion of sleep parameters (with actigraphy sleep 
reports forming the focus). The use of actigraphy sleep report 
during consultation especially in those with an insomniarelated 
disorder appears to have a positive impact. However, at this point 
there are no published studies of community pharmacy using 
actigraphy sleep reports during the consultation for sleeprelated 
disorders; hence the results of this intervention could not be 
compared with similar situations and settings. However, this 
approach is almost similar to the “gold standard” treatment 
for insomnia, that is, the cognitive behavioral therapy (CBTI), 
which includes consultation to help patients change their 
sleep habits.[34] CBTI which combines elements such as sleep 
education, sleep hygiene, sleep restriction, and cognitive 
therapy is suggested to be effective in addressing the issues with 
sleep onset and maintenance of sleep in insomnia patients in 
primary healthcare settings.[35,36] One study which evaluated 
the effectiveness of CBTI (by evaluating changes in the ISI 
mean scores), found that the scores for the CBTI group was 
significantly reduced from pretreatment to posttreatment.[37] 
Having significantly reduced mean scores for ISI in this study, 
the findings could suggest that this current study might be 
noninferior to the study that used CBTI approach as an 
intervention. Although with a different setting and study 
population, this intervention study has shown that it is possible 
to adapt this approach into the community pharmacy workflow 
in providing an intervention that is more convenient and easier 
to conduct.
As part of the intervention, actigraph was also used to compare 
pre and postmean sleep parameters (SE%, TST, SOL, and 
Table 3: Comparisons within groups for sleep scale scores
Instrument Group/
pre/post
Mean (SD)
scores
Mean 
differences
95% CI of 
the difference
Significant 
(two tailed), P
ESS ICG
Pre 5.20 (5.47) 1.15 − 0.12-2.42 0.074
Post 4.05 (4.14)
UCG
Pre 4.19 (4.33) − 0.24 − 0.87-0.42 0.459
Post 4.43 (4.15)
ISI ICG
Pre 15.45 (6.68) 4.35 1.96-6.74 0.001*
Post 11.10 (5.80)
UCG
Pre 15.95 (5.19) 0.71 − 0.20-1.62 0.118
Post 15.24 (5.15)
* P< 0.05. ICG n= 20, UCG n= 21. Pre - baseline, Post - week 2. 
SD: Standard deviation, ICG: Intervention care group, UCG: Usual care 
group, ESS: Epworth Sleepiness Scale, ISI : Insomnia Severity Index, 
CI : Confidence interval
Table 4: Comparisons of SE%, TST, SOL and NWAK mean scores in actigraphy assessments at two time points in the ICG (n= 20)
Pre/post Mean (SD) Mean difference 95% CI  of the mean difference Significant (two tailed), P
TST Pre 6.98 (1.35) 0.12 − 0.31-0.54 0.573
Post 6.86 (1.47)
SOL Pre 17.85 (10.04) − 2.15 − 5.36-1.06 0.178
Post 20.00 (10.74)
NWAK Pre 4.32 (2.58) 0.28 − 0.44-0.99 0.425
Post 4.04 (2.47)
SE% Pre 77.03 (9.92) − 0.61 − 4.16-2.93 0.723
Post 77.63 (11.19)
Distribution of subjects, SE% 4 level categorical variable, n (%)
Very good sleeper Fairly good sleeper Fairly bad sleeper Very bad sleeper
Pre Nil 5 (25) 7 (35) 8 (40)
Post 3 (15) 4 (20) 1 (5) 12 (60)
Pre - Week 1, Post - Week 2. Normal ranges (values): TST: 7-9 h,[28,29] SOL: 10-20 min - based on proprietary software, NWAK: 0-16 times/
night - based on proprietary software, SE%: ≥ 85%.[30,31] Cut-off points for converting continuous variables collected by actigraphy to 4-level 
categorical variable[18]: Very good sleeper: > 90%, fairly good sleeper: 85-90%, fairly bad sleeper: 80-84%, very bad sleeper: < 80. SE%: Sleep 
efficiency in percentage, TST: Total sleep time, SOL: Sleep onset latency, NWAK: Number of nocturnal awakenings, ICG: Intervention care group, 
CI : Confidence interval
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NWAK) scores to identify changes in sleep/wake patterns in 
the ICG and evaluated the effectiveness of the intervention, as 
conducted in previous studies.[32,38,39] Although, as a whole, the 
findings could not observe significant differences, these are still 
need to be interpreted with caution as there may be significant 
discrepancies for some individuals, but was not observed in 
this study. The type of actigraph model and accompanying 
proprietary algorithm from the software, the sensitivity level 
and use of the nondominant and dominant wrist, may also 
have affected the actigraphy results in this study.[33]
In research and clinical settings, the literature suggests 
combining actigraph monitoring with a sleep diary to better 
characterize sleep/wake patterns in individuals with disturbed 
sleep.[17,40] Similar sleep parameter results for SOL and NWAK 
found in both sleep diary and actigraphy data suggests 
that actigraph is an appropriate objective sleep assessment 
instrument to validate SOL and NWAK in this study. However, 
a significant difference was found when comparing postTST 
mean scores between actigraphy data and sleep diary at week 
2. This is in accordance with previous studies,[41,42] which found 
significant differences when comparing TST between these 
two tools.
Overall, actigraphy data revealed that mean scores for SE% were 
lower than the cutoff value at both pre and postassessment; 
suggesting that in the ICG, at both time points, the mean scores 
for SE% could not reach the expected level for a “good sleeper.” 
However, this study found a negative correlation between 
SE% and SOL, which meant that those who took longer to 
fall asleep (longer SOL) had a lower SE%. This correlation is 
supported by one study[43] that also found a negative correlation 
between sleep quality and SOL. However, to better confirm 
this, studies using actigraphy data from larger samples should 
be conducted.
Limitation
Due to its exploratory nature, one obvious limitation is the fact 
that the study has relatively small number of participants despite 
a priori power calculation. With a small sample size, caution 
must be applied, as the findings might not be transferable to 
the general community. However, the results could be used 
as representative of the customers experiencing certain sleep 
disorders attending the community pharmacy.
One more limitation is the time frame of the whole study. 
An extension of the study over a longer time frame would be 
supportive to test the hypotheses. With a longer time frame to 
recruit the participants, recruitment of a larger sample size would 
be possible. The challenges also were due to constraints outside of 
the research team’s control, such as difficulties in recruiting the 
community pharmacies and participants within the time frame.
Another limitation is that the study was designed to recruit 
participants conveniently, and no randomization was conducted. 
The participants in the intervention group were aware of the 
intervention hence some of them might have reacted according 
to the researcher’s expectation. This can be explained as 
“Hawthorne effect;” a phenomenon which suggests that study 
subjects’ behavior are altered by the subjects’ awareness that they 
are being studied or that they received additional attention.[44]
Conclusion
Although the intervention had limited success with regards 
to participant outcomes, it has offered some insights into the 
development of a community pharmacybased intervention 
to improve the management of sleep disorders in the future. 
The study demonstrated that actigraphy is a method that is 
convenient to be used at the community pharmacy and the 
use of actigraphy sleep reports in generating objective sleep/
wake data to assist the pharmacists during consultation sessions 
related to sleeping disorders, can positively provide support. 
The findings from this study have important implications for 
recommending further research using a larger sample size and 
different study populations, before the effectiveness of the 
“model of care” can be clearly understood. This study hence 
concluded that for a communitybased intervention to be 
effective, and yet be able to be widely implemented, it needs 
to be practical, convenient for use and, easily conducted and 
implemented by the pharmacists and pharmacy staff.
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Table 5: Mean differences in sleep parameters of actigraph 
and sleep diary reported at two time points in the ICG (n= 20)
Sleep 
parameters
Mean differences in sleep parameters 
(actigraph versus sleep diary) (95% CI)
Significant 
(two tailed), P
Pre (week 1)
TST − 0.25 (− 0.60-0.10) 0.153
SOL − 2.41 (− 7.58-2.75) 0.341
NWAK 0.33 (− 0.48-1.13) 0.406
Post (week 2)
TST − 0.52 (− 0.72-− 0.33) 0.001*
SOL − 2.15 (− 5.83-1.53) 0.237
NWAK 0.62 (− 0.19-1.43) 0.129
* P< 0.05. ICG: Intervention care group, TST: Total sleep time, 
SOL: Sleep onset latency, NWAK: Number of nocturnal awakenings, 
CI :  Confidence interval
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